Skip to main content
Premium Trial:

Request an Annual Quote

Diaxonhit, Boehringer Ingelheim Collaborate on Cancer Therapeutic Targets

NEW YORK (GenomeWeb News) – Diaxonhit today announced an agreement with Boehringer Ingelheim to discover and characterize novel splice variants that potentially could be therapeutic targets for oncology.

Paris-based Diaxonhit will use its SpliceArray discovery platform to identify potential targets and then build a database of specific splice variants. Boehringer Ingelheim has the option to buy the rights to research, develop, and commercialize any targets discovered by Diaxonhit.

SpliceArray are microarrays for determining the expression of individual alternatively spliced transcripts. Terms of the deal were not disclosed.

Diaxonhit was formed late last year when Exonhit bought inGen BioSciences for about $23.1 million.